-+ 0.00%
-+ 0.00%
-+ 0.00%

Alnylam Q2 GAAP net income swings to USD 164.49 million; revenue rises 67% to USD 1.29 billion vs Q2 FY25

PUBT·07/30/2026 12:04:38
Listen to the news
Alnylam Q2 GAAP net income swings to USD 164.49 million; revenue rises 67% to USD 1.29 billion vs Q2 FY25
  • Alnylam posted Q2 revenue of USD 1.29 billion, up 67% year over year, as net product revenues rose 74% to USD 1.17 billion.
  • GAAP net income swung to USD 164.49 million; GAAP EPS was USD 1.23.
  • AMVUTTRA net product revenues more than doubled to USD 1.01 billion, lifting total TTR net product revenues 89% to USD 1.03 billion.
  • Full-year 2026 TTR net product revenue guidance was cut to USD 4.2 billion-USD 4.5 billion; total net product revenue outlook lowered to USD 4.7 billion-USD 5.1 billion.
  • CEO Yvonne Greenstreet cited normalized second-line volume after early pent-up demand; Alnylam signed an exclusive AMVUTTRA China deal with BeOne.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alnylam Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607300800BIZWIRE_USPR_____20260730_BW523296) on July 30, 2026, and is solely responsible for the information contained therein.